Back to today’s briefing

Story perspectives

Immunotherapy Timing Cuts Lung Cancer Risks by Over 50%

12/9/2025

26 2 Full Breakdown

Summary

Story summary

The study, published in Cancer, found immunotherapy timing affects survival in advanced small cell lung cancer, with treatment before 3 p.m. linked to a 52% lower risk of progression and a 63% lower risk of death.
Dr. Yongchang Zhang of Central South University led the study, enrolling nearly 400 patients.
Researchers say timing could improve outcomes with no extra costs.
They urge more studies on circadian rhythms in cancer therapies.

1 of 1

Story summary

The study, published in Cancer, found immunotherapy timing affects survival in advanced small cell lung cancer, with treatment before 3 p.m. linked to a 52% lower risk of progression and a 63% lower risk of death.
Dr. Yongchang Zhang of Central South University led the study, enrolling nearly 400 patients.
Researchers say timing could improve outcomes with no extra costs.
They urge more studies on circadian rhythms in cancer therapies.